• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Collegium Internationale Allergologicum >Allergenicity and Immunogenicity of Commercially Available Allergoid Products for Birch Pollen Immunotherapy
【24h】

Allergenicity and Immunogenicity of Commercially Available Allergoid Products for Birch Pollen Immunotherapy

机译：用于桦木花粉免疫疗法的市售全体药物的过敏性和免疫原性

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The rationale for chemically modifying allergens (allergoids) is to reduce allergenicity and mamtain immunogenicity, A statistical evaluation of adverse events reported to the German health authority over a 10 year period, however, did not indicate higher safety, of allergoids compared with intact allergens. Four commercially available allergoids were compared to the intact allergen product Alutard SQ~R by solid phase IgE inhibition assays and histamirie release assays to investigate allergenicity, and immunogenicity by human T-cell proliferation and measurement of IgG titers following mouse immunizations. The SIT products were normalized with respect to the manufacturers recommended maintenance dose: Two of four allergoids tested did not show reduced IgE binding in the solid phase IgE inhibition analyses compared with the intact allergen product; different slopes of the inhibition curves for the allergoids indicate structural changes of the epitope composition. One of the four allergoid products did not show reduced histamine release compared to the intact allergen extract, patient-to-patient variation in histamine release assays was very large. All allergoids showed a reduced response in standard T-cell stimulation assayscompared to Alutard SQ~R regardless of the cell type used for antigen presentation (PBL or DC). All allergoids showed reduced capacity to induce allergen-specific IgG responses in mice. Commercial allergoid preparations do not fulfil the allergoid concept, since all allergoids showed reduced immunogenicity, and one allergoid did not show reduced allergenicity.
机译：化学改性过敏原的理由是降低过敏性和分歧性免疫原性，对德国卫生局报告的不良事件的统计评估在10年期内没有表明与完整过敏原相比过敏剂的安全性更高。将四种可商购的全体检查通过固相IgE抑制测定和Histamirie释放测定进行了与固相IgE抑制测定和由人T细胞增殖的过敏性和免疫原性进行了比较，并通过小鼠免疫后的IgG滴度的免疫原性。与制造商建议的维护剂量标准化了静坐产品：与完整的过敏原产品相比，测试的四种过敏剂中的两个过敏剂未显示在固相IgE抑制分析中的降低;抗体检查曲线的不同斜率表明表位组成的结构变化。与完整的过敏原提取物相比，四个过敏产品中未表明组胺释放的一项，患者对组胺释放测定的患者对患者的变化非常大。无论用于抗原呈递（PBL或DC）的细胞类型，所有致甲脂蛋白都显示出对ALUTARD SQ〜R的标准T细胞刺激ASAYSEAYSEAYSEAYSEAYSEAYS对响应的响应。所有血压检查表明，诱导小鼠过敏原特异性IgG反应的能力降低。商业致敏制剂不能满足过敏反应的概念，因为所有的血压检查都会降低免疫原性，并且一个过敏剂未显示出降低过敏性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号